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Although cancers develop and progress in immunocompetent hosts, immunological therapies for cancer have been
proposed as alternative or complementary approaches to
more standard therapy. It was initially thought that tumors
were silent to the immune system, and that breaking immunological tolerance could result in immune-mediated tumor
rejection. However, we have learned that cancer patients have
preexisting immune responses against their tumor antigens
which, nevertheless, fail to protect them, in part because
of increased activity of the immune suppressor cells such
as myeloid-derived suppressor cells (MDSC). Attempts to
develop combinatorial therapies by depleting suppressor
cells or blocking suppressor pathways and at the same time
actively inducing immune responses in vivo or adoptively
transferring tumor-specific T cells have largely failed. Very
limited success has been achieved only against melanoma,
using adoptive T-cell therapy, or prostate cancer, using a
vaccine which improves patient survival but has no apparent
inhibitory eﬀect on disease progression. Further progress
in the immunotherapy of cancer has been halted because
of a poor understanding of the cellular components of the
immune responses working together in favor of or against the
tumors, as well as our inability to reliably reprogram immune
responses towards the most eﬀective phenotypes against
cancer. This special issue is focused on understanding the
escape mechanisms that malignant cells develop to hijack

antitumor immune responses as well as strategies to overcome tumor escape. Four main areas that are covered in this
issue include the following.
Opposing Functions of the Immune System in Tumor Inhibition
and Tumor Progression. Robert Schreiber proposed the term
“cancer immunoediting” in order to broadly describe the
dual host-protecting and tumor-sculpting actions of the
immune system that not only survey for, and eliminate,
nascent malignant cells but also shape neoplastic disease
through equilibrium and escape mechanisms. In this issue,
M. Aris et al. discuss the dual function of the immune system
in controlling and promoting tumor progression in cutaneous melanoma. They propose that tumor evolution is
because of a continuous feedback between tumor cells and
their environment, and thus diﬀerent combinatorial therapeutic approaches can be implemented according to the
tumor stage. A. Amedei et al. discuss recent knowledge on the
contribution of T cells in oncogenesis. They review the
diﬀerent types, “friend or foe,” of T-cell response in gastric
cancer.
Tumor-Associated Modulation of Immune Checkpoint Molecules. Upon activation, T cells develop negative feedback regulatory mechanisms in order to avoid overstimulation. These
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include the expression of checkpoint molecules such as PD-1
and CTLA-4. T cells that recognize and respond to tumor
antigens produce IFN-γ. A dual function of IFN-γ is the
induction of apoptosis in target cells and upregulation of PDL1 that interacts with PD-1 positive T cells, thereby resulting
in the exhaustion of tumor-reactive T cells. Expression of
CTLA-4 on activated T cells also results in T-cell anergy
upon interaction with costimulatory molecules on DCs. S.
Sapozink et al. describe new immunomodulatory approaches
currently in the development pipeline, with focus on the
novel CEACAM1 immune checkpoint, and compare its
potential to the extensively described lymphocyte inhibitory
targets, CTLA4 and PD-1. E. Rozali et al. provide an extensive
review of the literature on the immunoregulatory role of
PD-L2 in cancer-induced immune suppression and discuss
the results of recent studies targeting PD-L2 in cancer.
L. Cruz-Merino et al. discuss immune escape mechanisms in
Hodgkin’s lymphoma (HL) and summarize the clinical,
histological, pathological, and biological factors in HL, with
special emphasis on the improvement of prognosis and their
impact on treatment strategies. L. Farnault et al. introduce
various mechanisms involved in the escape of hematological
malignancies from NK-cell surveillance. These include NKcell qualitative and qualitative deficiencies that occur through
modulating the inhibitory and activating stimuli.
Tumor-Induced Immune Suppression. Malignant cells produce cytokines and chemokines that facilitate the expansion
or diﬀerentiation of immune suppressor cells such as Tregs,
MDSC, and M2 macrophages. G. Zhou and H. Levitsky summarize the findings from some recent preclinical and clinical
studies, focusing on how tumor cells advance their survival
and expansion by hijacking therapy-induced immune eﬀector mechanisms that would otherwise mediate their destruction. A particularly interesting notion that is touched upon
involves tumor-independent treatment-induced homeostatic
counter-regulation. M. Jadus et al. cover the escape mechanisms of bronchogenic lung cancer that must be overcome
before they can be successfully treated. They also review
the history of immunotherapy directed towards lung cancers. N. Hao et al. discuss the role of tumor-associated
macrophages including M1 and M2 subsets during tumour
progression and metastasis, highlighting the immunosuppressive role of M2 macrophages. V. Levina et al. investigate
the role of indoleamine 2,3-dioxygenase (IDO1) in tumor
escape and metastasis using 4T1 mammary carcinoma
model. They show that IDO1 can not only suppress antitumour immune responses but also promote tumour cell
proliferation.
Improved Immunotherapeutic Strategies to Overcome Tumor
Escape. Immunotherapy combined with blockade of
immune suppressor pathways has been developed to
overcome tumor-induced immune suppression. Cornelissen
et al. discuss the interplay between a dual function of the
immune responses against mesothelioma which can either
inhibit or stimulate tumor growth and review the challenges
associated with immunotherapy. They also discuss possible
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strategies and opportunities to overcome tumor escape.
R. Casalegno-Garduño et al. analyze the expression of the
leukemia-associated antigen receptor for hyaluronan acidmediated motility (RHAMM) in patients suﬀering from
acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Their results suggest that immunotherapies
like peptide vaccination or adoptive transfer of RHAMMspecific T cells might improve the immune response and
the clinical outcome in AML/MDS patients. S.Wallner et al.
summarize the current knowledge about the negative
regulatory role of Cbl-b in T-cell activation and its potential
therapeutic implications for cancer immunotherapy. H.
Nagai et al. demonstrate that sorafenib-induced Th1
dominance can prevent the escape of tumor cells from the
host immune system in liver cirrhosis (LC) patients with
advanced hepatocellular carcinoma (aHCC).
Overall, this special issue provides a well-rounded synopsis of representative research eﬀorts addressing the issues
related to “tumor escape and progression under immune
pressure.”
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